MedPath

Nevirapine

Generic Name
Nevirapine
Brand Names
Viramune
Drug Type
Small Molecule
Chemical Formula
C15H14N4O
CAS Number
129618-40-2
Unique Ingredient Identifier
99DK7FVK1H
Background

A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Indication

For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients

Not Applicable
Completed
Conditions
Efficacy of Rilpivirine-based Regimens as Switch Therapy
Interventions
First Posted Date
2018-09-10
Last Posted Date
2018-09-10
Lead Sponsor
Mahidol University
Target Recruit Count
106
Registration Number
NCT03664440
Locations
🇹🇭

Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV

Completed
Conditions
Efavirenz
Medication Adherence
Child Behavior
Drug-Related Side Effects and Adverse Reactions
Cognitive Symptom
Interventions
Drug: Lopinavir-Ritonavir Drug Combination
First Posted Date
2017-07-24
Last Posted Date
2018-07-10
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
144
Registration Number
NCT03227653
Locations
🇹🇿

Mawenzi Regional Hospital, Moshi, Kilimanjaro Region, Tanzania

🇹🇿

Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro Region, Tanzania

🇹🇿

Kiboroloni Dispensary, Moshi, Tanzania

and more 3 locations

Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gaborone, Botswana

Phase 4
Completed
Conditions
Insulin Sensitivity
HIV
Diabetes Mellitus
Interventions
First Posted Date
2017-03-23
Last Posted Date
2022-07-20
Lead Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Target Recruit Count
495
Registration Number
NCT03088410
Locations
🇧🇼

Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana

Antiretroviral Regime for Viral Eradication in Newborns

Phase 4
Completed
Conditions
HIV/AIDS and Infections
Interventions
First Posted Date
2016-03-18
Last Posted Date
2022-09-28
Lead Sponsor
National Center for Women and Children's Health, China CDC
Target Recruit Count
600
Registration Number
NCT02712801
Locations
🇨🇳

Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

🇨🇳

Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China

🇨🇳

Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

and more 2 locations

Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

Phase 4
Completed
Conditions
HIV
Interventions
Drug: LPV/r
First Posted Date
2015-05-01
Last Posted Date
2020-08-04
Lead Sponsor
Columbia University
Target Recruit Count
73
Registration Number
NCT02431975
Locations
🇿🇦

Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa

Early Infant HIV Treatment in Botswana

Phase 2
Active, not recruiting
Conditions
HIV
Pediatric AIDS
Interventions
First Posted Date
2015-02-24
Last Posted Date
2024-12-19
Lead Sponsor
Harvard School of Public Health (HSPH)
Target Recruit Count
67
Registration Number
NCT02369406
Locations
🇧🇼

Botswana Harvard HIV/AIDS Institute Partnership, Gaborone, Botswana

A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation

Completed
Conditions
HIV
Pregnancy
Breastfeeding
Interventions
First Posted Date
2014-10-21
Last Posted Date
2017-09-06
Lead Sponsor
Adeniyi Olagunju
Target Recruit Count
460
Registration Number
NCT02269462
Locations
🇳🇬

St Monica's Hospital, Adikpo, Benue State, Nigeria

🇳🇬

Bishop Murray Medical Centre, Makurdi, Benue State, Nigeria

🇳🇬

St Mary's Hospital, Okpoga, Benue State, Nigeria

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

Phase 1
Completed
Conditions
HIV-1
Interventions
First Posted Date
2014-07-28
Last Posted Date
2015-08-25
Lead Sponsor
Ratiopharm GmbH
Target Recruit Count
46
Registration Number
NCT02202005
Locations
🇬🇧

Chelsea and Westminster NHS Foundation Trust, London, United Kingdom

Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects

First Posted Date
2014-07-18
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
92
Registration Number
NCT02194179

Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens

Completed
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-16
Last Posted Date
2014-07-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
55
Registration Number
NCT02191319
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy